New oral GLP‑1 and safety tools

These drugs copy a gut signal your body already uses after you eat. That signal tells the pancreas to release insulin, slows how fast food leaves the stomach, and helps the brain register fullness sooner. (my.clevelandclinic.org) For years, the strongest version of that trick usually came in a pen injector, not a pill. Drugs like semaglutide and tirzepatide turned weekly shots into a huge business because they lowered blood sugar and often cut body weight too. (fda.gov 1) (fda.gov 2) Now Eli Lilly has pushed that market one step further with Foundayo, the brand name for orforglipron, a once-daily pill now being offered in the United States for adults with obesity or overweight plus weight-related medical problems. Lilly said on April 9, 2026 that the drug is available through LillyDirect and telehealth partners including Ro and LifeMD. (prnewswire.com) (marketwatch.com) (markets.businessinsider.com) The pill matters because swallowing one tablet each morning is simpler than learning injection technique, storing pens, and keeping up with weekly dosing. Orforglipron is also a small-molecule drug rather than a peptide, which is why Lilly has been able to package it as a tablet instead of a refrigerated shot. (thelancet.com) (prnewswire.com) Lilly’s late-stage obesity studies put real numbers behind that convenience. In the company’s release on approval and in coverage of the phase 3 program, placebo-adjusted weight loss was reported at roughly 9 to 11 percentage points over 72 weeks, with stomach side effects like nausea, vomiting, diarrhea, and constipation still the most common tradeoff. (ajmc.com) (clinicaladvisor.com) As more people start these medicines, a second business is appearing next to the drugs themselves: home checkups. Choose Health said on April 9, 2026 that it launched mail-in monitoring panels for people taking Ozempic, Wegovy, and Mounjaro to track liver, kidney, and metabolic markers from home. (prnewswire.com) That tells you how the market is changing. The first wave was “get the prescription,” and the next wave is “show me the lab numbers,” especially for people using telehealth, switching doses, or staying on treatment for months. (prnewswire.com) (markets.businessinsider.com) At the same time, regulators are moving the other direction: more access, but tighter guardrails. India’s drug authorities issued a public advisory on April 1, 2026 warning that glucagon-like peptide-1 drugs should not be taken without a prescription and cannot be sold over the counter. (static.pib.gov.in) (tribuneindia.com) The Indian notice also named the risks that have followed the hype: pancreatitis, gallbladder problems, kidney injury from dehydration, and thyroid-related warnings, while saying only specialists such as endocrinologists, internal medicine doctors, and cardiologists should prescribe them there. (static.pib.gov.in) (cnbctv18.com) So the new shape of the glucagon-like peptide-1 market is easy to see. One company is selling a weight-loss pill, another is selling at-home blood panels around the same class of drugs, and regulators are reminding people that a medicine powerful enough to change appetite and blood sugar is still not something to buy like vitamins. (prnewswire.com 1) (prnewswire.com 2) (static.pib.gov.in)